No­vo Nordisk se­cures FDA ap­proval of RNAi ther­a­py from $3.3B Dicer­na takeover

Two years lat­er, No­vo Nordisk’s $3.3 bil­lion buy­out of Dicer­na Phar­ma­ceu­ti­cals’ RNAi plat­form is be­gin­ning to pay off.

No­vo scored an ap­proval on Mon­day for ne­dosir­an, an RNAi ther­a­py de­vel­oped by Dicer­na to treat a rare kid­ney dis­ease called pri­ma­ry hy­per­ox­aluria type 1 (PH1). The drug, mar­ket­ed as Rivfloza, is ex­pect­ed to be avail­able in ear­ly 2024, No­vo said in an an­nounce­ment.

PH is a ge­net­ic dis­ease marked by an ex­ces­sive pro­duc­tion of ox­alate, a sub­stance that can com­bine with cal­ci­um to cause kid­ney stones. Some pa­tients may need dial­y­sis, while con­tin­ued ox­alate buildup can al­so dam­age oth­er or­gans. Rivfloza is ap­proved to low­er uri­nary ox­alate lev­els in adults and chil­dren 9 years and old­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.